ClinicalTrials.gg
RecruitingNCT07612020Updated May 28, 2026

A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants

A Phase 1 interventional study of empasiprubart SC AI and empasiprubart IV in Healthy Volunteers, sponsored by argenx. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by argenx · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to see how the body reacts to empasiprubart, administered using an autoinjector (AI). The study will also look at other effects of empasiprubart, how it works in the body, and if it is safe.

The study consists of 2 parts: parts A and B. In part A, eligible participants will be randomized to receive empasiprubart SC AI via abdomen, empasiprubart SC AI via thigh, or empasiprubart IV (intravenously). In part B, eligible participants will be randomized to receive empasiprubart SC AI via abdomen or empasiprubart IV.

Participants from part A will be in the study for approximately up to 37 weeks . Participants from part B will be in the study for up to approximately 43 weeks.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least the local legal age of consent and aged 18 to 65 years, inclusive, when signing the ICF.
  • Has a body weight between 50 and 120 kg and a between 18 and 35 kg/m2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Has any current or past medical or psychiatric condition that, in the investigator's opinion, would confound the study results or put the participant at undue risk.
  • Clinical diagnosis of SLE. For participants with an antinuclear antibody titer of ≥1:80 and a positive anti-double-stranded DNA and/or positive anti-Smith result at screening, an SLE diagnosis must be ruled out before the first IMP administration.
  • Previously participated in an empasiprubart clinical study and received at least 1 dose of IMP.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Open-label treatment period (part A): empasiprubart SC AI (via abdomen)

    Participants randomized to receive empasiprubart SC AI via abdomen.

    Biological: empasiprubart SC AI

  • Experimental
    Open-label treatment period (part A): empasiprubart SC AI (via thigh)

    Participants randomized to receive empasiprubart SC AI via thigh.

    Biological: empasiprubart SC AI

  • Experimental
    Open-label treatment period (part A): empasiprubart IV

    Participants randomized to receive empasiprubart IV.

    Biological: empasiprubart IV

  • Experimental
    Open-label treatment period (part B): empasiprubart SC AI

    Participants randomized to receive empasiprubart IV and empasiprubart SC AI.

    Biological: empasiprubart SC AI · Biological: empasiprubart IV

  • Experimental
    Open-label treatment period (part B): empasiprubart IV

    Participants randomized to receive empasiprubart IV.

    Biological: empasiprubart IV

Interventions

  • Biologicalempasiprubart SC AI

    Subcutaneous injection of empasiprubart via Autoinjector (AI).

  • Intravenous infusion of empasiprubart

06

What researchers measure

Primary outcomes

  1. aBA via abdomen as assessed by AUC0-inf SC versus AUC0-inf IV

    aBA = absolute bioavailability; AUC0-inf=area under the concentration-time curve from time 0 to infinity; PK = pharmacokinetics; SC = subcutaneous, IV = intravenous

    Time frame: Up to 33 weeks

  2. aBA via thigh as assessed by AUC0-inf SC versus AUC0-inf IV

    aBA = absolute bioavailability; AUC0-inf=area under the concentration-time curve from time 0 to infinity; PK = pharmacokinetics; SC = subcutaneous, IV = intravenous

    Time frame: Up to 33 weeks

  3. Ctrough at week 8

    Ctrough = trough concentration

    Time frame: Up to 8 weeks

Secondary outcomes

  1. empasiprubart Cmax

    Cmax = maximum observed concentration

    Time frame: Up to 33 weeks

  2. AUCw4-8 over time

    AUCw4-8 = area under the concentration-time curve from week 4 to week 8

    Time frame: Up to 39 weeks

  3. Cavg over time

    Cavg = average concentration

    Time frame: Up to 39 weeks

  4. Ctrough over time

    Ctrough = trough concentration

    Time frame: Up to 39 weeks

  5. Percentage change from baseline in free C2 and total C2 over time

    C2 = complement component 2

    Time frame: Up to 33 weeks (Part A) + up to 39 weeks (Part B)

  6. Incidence of ADA against empasiprubart in serum

    ADA = antidrug antibody(ies)

    Time frame: Up to 33 weeks (Part A) + up to 39 weeks (Part B)

  7. Incidence of AEs, SAEs, and AEs leading to empasiprubart discontinuation

    AE=adverse event; SAE=serious adverse event

    Time frame: Up to 33 weeks (Part A) + up to 39 weeks (Part B)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 28, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Oct 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07612020
Lead sponsor
argenx
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Mar 16, 2026
Primary completion
Mar 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
May 28, 2026

Study contacts

Sabine Coppieters, MD
Contact
clinicaltrials@argenx.com
857-350-4834

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empasiprubart

Start the discussion